Bivalirudin versus unfractionated heparin: a meta-analysis of patients receiving percutaneous coronary intervention for acute coronary syndromes

Mohamed Farag,1,2 Diana A Gorog,1,2,3 Abhiram Prasad,4 Manivannan Srinivasan1

ABSTRACT
Objective: Acute coronary syndrome (ACS) encompasses ST segment elevation myocardial infarction (STEMI), with generally high thrombus burden and non-ST segment elevation ACS (NSTE-ACS), with lower thrombus burden. In the setting of percutaneous coronary intervention (PCI) for ACS, bivalirudin appears superior to unfractionated heparin (UFH), driven by reduced major bleeding. Recent trials suggest that the benefit of bivalirudin may be reduced with use of transradial access and evolution in antiplatelet therapy. Moreover, a differential role of bivalirudin in ACS cohorts is unknown.

Methods: A meta-analysis of randomised trials comparing bivalirudin and UFH in patients with ACS receiving PCI, with separate analyses in STEMI and NSTE-ACS groups. Overall estimates of treatment effect were calculated with random-effects model.

Results: In 5 trials of STEMI (10 358 patients), bivalirudin increased the risk of acute stent thrombosis (ST) (OR 3.62; CI 1.95 to 6.74; p<0.001) compared with UFH. Bivalirudin reduced the risk of major bleeding only when compared with UFH plus planned glycoprotein IIb/IIIa inhibitors (GPI) (OR 0.49; CI 0.36 to 0.67; p=0.00001). In 14 NSTE-ACS trials (25 238 patients), there was no difference between bivalirudin and UFH in death, myocardial infarction or ST. However, bivalirudin reduced the risk of major bleeding compared with UFH plus planned GPI (OR 0.52; CI 0.43 to 0.62; p=0.00001), or UFH plus provisional GPI (OR 0.68; CI 0.46 to 1.01; p=0.05). The reduction in major bleeding with bivalirudin was not related to vascular access site.

Conclusions: Bivalirudin increases the risk of acute ST in STEMI, but may confer an advantage over UFH in NSTE-ACS while undergoing PCI, reducing major bleeding without an increase in ST.

BACKGROUND
Bivalirudin is an intravenous direct thrombin inhibitor that is widely used in the setting of percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS).1,2 Randomised trials have demonstrated that bivalirudin is superior to unfractionated heparin (UFH) in reducing net adverse cardiac events, mainly due to a reduction in major bleeding.3-5 This is an important consideration since bleeding related to PCI has been associated with significant deleterious short-term and long-term consequences.6-8 However, over the past decade, the rates of major or clinically significant bleeding have

KEY QUESTIONS
What is already known about this subject?
▶ The use of bivalirudin during percutaneous coronary intervention (PCI) has been the subject of much debate recently.

What does this study add?
▶ Our meta-analysis should help clinicians when selecting a periprocedural anticoagulant in different acute coronary syndrome (ACS) cohorts undergoing PCI (ie, in ST segment elevation myocardial infarction [STEMI] vs non-ST segment elevation [NSTE] ACS).

How might this impact on clinical practice?
▶ This will probably have a great impact on clinical practice as this meta-analysis suggests that in patients with STEMI, with generally high thrombus burden and with the increasing use of transradial approach and more potent oral antiplatelet therapy, bivalirudin does not appear to be superior to unfractionated heparin, especially with the provision of glycoprotein IIb/IIIa inhibitors (GPI) as currently recommended. In comparison, in patients with NSTE-ACS with lower thrombus burden, our meta-analysis suggests that bivalirudin may be superior to unfractionated heparin with provisional GPI use with regard to bleeding risk, but does not reduce risk of ischaemic events.


doi:10.1136/openhrt-2015-000258

Received 3 April 2015
Revised 7 August 2015
Accepted 27 August 2015

1Department of Cardiology, East and North Hertfordshire NHS Trust, Hertfordshire, UK
2Postgraduate Medical School, University of Hertfordshire, Hertfordshire, UK
3National Heart & Lung Institute, Imperial College, London, UK
4Cardiovascular and Cell Sciences Research Institute, St George’s, University of London, London, UK

Correspondence to
Dr Manivannan Srinivasan;
manivannan.srinivasan@nhs.net

Open Heart: first published as 10.1136/openhrt-2015-000258 on 1 October 2015. Downloaded from http://openheart.bmj.com/ on 1 December 2015 by guest. Protected by copyright.
decreased markedly as a result of innovations in PCI, including the increasing use of transradial vascular access and modifications in adjunct pharmacotherapy. With respect to the latter, introduction of potent oral antiplatelet agents have decreased the routine use of glycoprotein IIb/IIIa inhibitors (GPI) in ACS, with current opinion favouring their use in patients with large thrombus burden, insufficient oral antiplatelet therapy, or as a bailout for complications.10,11 Perhaps, as a result of this evolution in clinical practice, recent trials suggest that the previous benefit observed with bivalirudin may be substantially reduced in the contemporary PCI setting.10,11

Several trials of bivalirudin have reported a small increase in the risk of myocardial infarction (MI) and/or stent thrombosis (ST) in patients with ACS undergoing PCI.4,5,12,13 However, the study designs were not directly comparable as some of these trials used routine GPI in the UFH arm compared with provisional GPI use in the bivalirudin arm.4,5,12,13 Thus, the net clinical benefit of bivalirudin use is likely to depend on the relative risk of ischaemic versus bleeding complications.

The main beneficial effect of potent antithrombotic therapy would be expected in the setting of large thrombus burden. Since ACS comprises of both ST segment elevation MI (STEMI), with generally high thrombus burden, and non-ST segment elevation MI (NSTEMI), and NSTE-ACS, who underwent PCI. Since ACS encompasses a wide spectrum of disease, the trials referred to as STEMI also included some patients with non-STEMI (NSTEMI), and NSTE-ACS trials also included patients with stable angina undergoing elective PCI. However, similar treatment strategies were employed for all patients in these trials. Exclusion criteria were as follows: studies that used fibrinolytic therapy, studies that used balloon angioplasty only, studies that primarily addressed dosing or timing issues, small studies including ≤50 patients, studies that included patients with stable angina only, and studies that reported no clinical outcomes (see online supplementary figure S1).

The PubMed/Medline, Embase, Scopus and Cochrane Central Register of Controlled Trials databases were searched until March 2015, without language restrictions. Eligible studies were identified with the following search terms: bivalirudin, Angiomax, Hirulog, heparin, anticoagulation, primary percutaneous coronary intervention, percutaneous coronary intervention, coronary intervention, coronary angioplasty, stent, acute coronary syndrome, myocardial infarction, unstable angina, randomly, random and randomised controlled trial. We also searched reference lists of the retrieved articles to identify other eligible studies. Online oral presentations and expert slide presentations were also examined.

Two investigators independently reviewed all titles, or titles and abstracts from the search results to identify articles according to fulfillment of inclusion criteria. Selected trials were compared, and disagreement was resolved by team discussion and consensus. Data extraction was carried out independently and in duplicate by the study investigators. Results of data extraction were then compared, and discrepancies resolved by discussion. If results were incomplete or unclear, the study authors were contacted. Articles finally selected for the review were checked to avoid inclusion of data published in duplicate. Relevant data was collected on baseline characteristics, and clinical outcomes at baseline and end of follow-up. We investigated efficacy end points of death, MI (including Q wave and non-Q wave), early ST including acute (<24 h) and subacute (≥24 h to 30 days), all up to 30 days posthospitalisation. Major bleeding at 30 days posthospitalisation was the safety end point of interest. The primary outcomes and definition of major bleeding for each trial is listed in online supplementary table S1.

Relevant studies were stratified according to the population studied into predominantly STEMI versus predominantly NSTEMI. For the purposes of the meta-analysis, results are presented for each ACS cohort independently. Where both ACS cohorts were studied with distinct results, the respective groups were analysed separately. Likewise, for trials in which there were three arms based on GPI use, major bleeding comparisons were analysed separately.

**Statistical analysis**

Outcomes are presented as ORs with 95% CIs. Pooled OR were calculated using a random-effects model by the method of DerSimonian and Laird.16 Heterogeneity was assessed using $\chi^2$ and $I^2$ tests. All analyses were performed with the intention-to-treat principle. We stratified results by key trial characteristics, including type of ACS (predominantly STEMI vs predominantly NSTEMI) and use of GPIs (predominantly planned in the UFH arm vs provisional in the bivalirudin arm, provisional in both arms, or planned in both arms). In sensitivity analysis, where possible, we included only trials which included patients predominantly with NSTEMI. We did
### Table 1  Characteristics of predominantly STEMI studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Patients (n)</th>
<th>PCI (%)</th>
<th>Bivalirudin (n)</th>
<th>UFH (n)</th>
<th>Bivalirudin design</th>
<th>UFH design</th>
<th>Female (%)</th>
<th>Mean age (year)</th>
<th>Follow-up (days)</th>
<th>GPI use (%)</th>
<th>Transradial (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HORIZONS-AMI, 2008&lt;sup&gt;13&lt;/sup&gt;</td>
<td>3602</td>
<td>93</td>
<td>1800</td>
<td>1802</td>
<td>Intravenous bolus of 0.75 mg/kg followed by an infusion of 1.75 mg/kg/h</td>
<td>Intravenous bolus of 60 U/kg with subsequent boluses targeted to ACT of 200–250 s</td>
<td>23</td>
<td>60</td>
<td>30</td>
<td>8</td>
<td>98</td>
</tr>
<tr>
<td>EUROMAX, 2013&lt;sup&gt;8&lt;/sup&gt;</td>
<td>2218</td>
<td>86</td>
<td>1089</td>
<td>1109</td>
<td>Intravenous bolus of 0.75 mg/kg followed by an infusion of 1.75 mg/kg/h</td>
<td>Intravenous bolus of 100 U/kg without GPI or 60 U/kg with GPI</td>
<td>24</td>
<td>62</td>
<td>30</td>
<td>12</td>
<td>69</td>
</tr>
<tr>
<td>Heat-PPCI, 2014&lt;sup&gt;10&lt;/sup&gt;</td>
<td>1812</td>
<td>82</td>
<td>905</td>
<td>907</td>
<td>Intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg/h. A rebolus of 0.3 mg/kg was administered if ACT values were &lt;225 s</td>
<td>Intravenous bolus of 70 U/kg with subsequent boluses if ACT values were &lt;200 s</td>
<td>28</td>
<td>63</td>
<td>28</td>
<td>13</td>
<td>15</td>
</tr>
<tr>
<td>BRIGHT*, 2015&lt;sup&gt;17&lt;/sup&gt;</td>
<td>2178</td>
<td>97</td>
<td>729</td>
<td>1449</td>
<td>Intravenous bolus of 0.75 mg/kg, followed by a continuous infusion of 1.75 mg/kg/h. If ACT was &lt;225 s, an additional bolus of 0.3 mg/kg was added</td>
<td>Intravenous bolus of 100 U/kg without GPI or 60 U/kg with GPI, with subsequent boluses if ACT values were &lt;200 s</td>
<td>18</td>
<td>58</td>
<td>30</td>
<td>4</td>
<td>53</td>
</tr>
<tr>
<td>BRAVE 4, 2014&lt;sup&gt;11&lt;/sup&gt;</td>
<td>548</td>
<td>92</td>
<td>271</td>
<td>277</td>
<td>Intravenous bolus of 0.75 mg/kg followed by an infusion of 1.75 mg/kg/h</td>
<td>Intravenous bolus of 70–100 U/kg with subsequent boluses according to ACT</td>
<td>23</td>
<td>61</td>
<td>30</td>
<td>3</td>
<td>6</td>
</tr>
</tbody>
</table>

*The trial involved three arms: bivalirudin alone, UFH alone, and UFH plus GPI.
ACT, activated clotting time; GPI, glycoprotein IIb/IIIa inhibitors; PCI, percutaneous coronary intervention; STEMI, ST segment elevation myocardial infarction; UFH, unfractionated heparin.
<table>
<thead>
<tr>
<th>Study</th>
<th>Patients (n)/population</th>
<th>PCI (%)</th>
<th>Bivalirudin (n)</th>
<th>UFH (%)</th>
<th>Bivalirudin design</th>
<th>UFH design</th>
<th>Female (%)</th>
<th>Mean age (year)</th>
<th>Follow-up (days)</th>
<th>GPI use (%)</th>
<th>Transradial Bivalirudin (%)</th>
<th>Transradial UFH (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>REPLACE-2, 2003</td>
<td>6010</td>
<td>98</td>
<td>2999</td>
<td>3011</td>
<td>Intravenous bolus of 0.75 mg/kg, followed by a continuous infusion of 1.75 mg/kg/h</td>
<td>Intravenous bolus of 65 U/kg</td>
<td>26</td>
<td>63</td>
<td>30</td>
<td>7</td>
<td>97</td>
<td>0</td>
</tr>
<tr>
<td>REPLACE-1, 2004</td>
<td>1056</td>
<td>100</td>
<td>532</td>
<td>524</td>
<td>Intravenous bolus of 0.75 mg/kg, followed by a continuous infusion of 1.75 mg/kg/h</td>
<td>Intravenous bolus of 60–70 U/kg adjusted to achieve and maintain an ACT of 200–300 s</td>
<td>30</td>
<td>64</td>
<td>2</td>
<td>71</td>
<td>73</td>
<td>3</td>
</tr>
<tr>
<td>PROTECT-TIMI 30, 2006</td>
<td>857</td>
<td>100</td>
<td>284</td>
<td>573</td>
<td>Intravenous bolus of 0.75 mg/kg, followed by a continuous infusion of 1.75 mg/kg/h with additional boluses to maintain ACT&gt;200 s</td>
<td>Intravenous bolus of 50 U/kg adjusted to achieve and maintain an ACT of 200–250 s</td>
<td>33</td>
<td>60</td>
<td>2</td>
<td>3</td>
<td>99</td>
<td>NR</td>
</tr>
<tr>
<td>ACUITY-PCI, 2007</td>
<td>7789</td>
<td>100</td>
<td>5228</td>
<td>2561</td>
<td>Intravenous bolus of 0.1 mg/kg and an infusion of 0.25 mg/ kg/h. An additional intravenous bolus of 0.5 mg/kg was administered before PCI, and the infusion was increased to 1.75 mg/kg/h</td>
<td>Intravenous bolus of 60 U/kg followed by an infusion of 12 U/kg/h to achieve and maintain an ACT of 200–250 s</td>
<td>27</td>
<td>63</td>
<td>30</td>
<td>53</td>
<td>97</td>
<td>6</td>
</tr>
<tr>
<td>ARNO, 2008</td>
<td>850</td>
<td>86</td>
<td>425</td>
<td>425</td>
<td>Intravenous bolus of 0.75 mg/kg, followed by a continuous infusion of 1.75 mg/kg/h</td>
<td>Intravenous bolus of 100 U/kg with or without additional boluses to achieve an ACT of 250–300 s</td>
<td>24</td>
<td>69</td>
<td>30</td>
<td>NR</td>
<td>NR</td>
<td>2</td>
</tr>
<tr>
<td>ISAR-REACT 3, 2008</td>
<td>4570</td>
<td>100</td>
<td>2289</td>
<td>2281</td>
<td>Intravenous bolus of 0.75 mg/kg, followed by a continuous infusion of 1.75 mg/kg/h</td>
<td>Intravenous bolus of 140 U/kg followed by a placebo infusion for the duration of the procedure</td>
<td>24</td>
<td>67</td>
<td>30</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>68</td>
</tr>
</tbody>
</table>

Continued
<table>
<thead>
<tr>
<th>Study</th>
<th>Patients (n)/ population</th>
<th>PCI (%)</th>
<th>Bivalirudin (n)</th>
<th>UFH (n)</th>
<th>Bivalirudin design</th>
<th>UFH design</th>
<th>Female (%)</th>
<th>Mean age (year)</th>
<th>Follow-up (days)</th>
<th>GPI use (%)</th>
<th>Transradial</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAPLES, 2009</td>
<td>Elective or urgent PCI</td>
<td>100</td>
<td>167</td>
<td>100</td>
<td>Intravenous bolus of 0.75 mg/kg, followed by a continuous infusion of 1.75 mg/kg/h with additional boluses to maintain ACT &gt; 250 s</td>
<td>Intravenous bolus of 70 U/kg with additional boluses to maintain ACT &gt; 250 s</td>
<td>35</td>
<td>65</td>
<td>30</td>
<td>1</td>
<td>100</td>
</tr>
<tr>
<td>TENACITY, 2011</td>
<td>Elective or urgent PCI</td>
<td>100</td>
<td>185</td>
<td>100</td>
<td>Intravenous bolus of 0.75 mg/kg, followed by a continuous infusion of 1.75 mg/kg/h</td>
<td>Intravenous bolus of 70 U/kg adjusted to achieve and maintain an ACT of 225 s</td>
<td>27</td>
<td>63</td>
<td>30</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>ISAR-REACT 4, 2011</td>
<td>NSTEMI</td>
<td>1721</td>
<td>860</td>
<td>861</td>
<td>Intravenous bolus of 0.75 mg/kg, followed by a continuous infusion of 1.75 mg/kg/h</td>
<td>Intravenous bolus of 70 U/kg</td>
<td>23</td>
<td>68</td>
<td>30</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>ARMYDA-7 BIVALVE, 2012</td>
<td>Elective or urgent PCI</td>
<td>401</td>
<td>198</td>
<td>203</td>
<td>Intravenous bolus of 0.75 mg/kg, followed by a continuous infusion of 1.75 mg/kg/h</td>
<td>Intravenous bolus of 75 U/kg</td>
<td>28</td>
<td>70</td>
<td>30</td>
<td>12</td>
<td>14</td>
</tr>
<tr>
<td>Deshpande et al.</td>
<td>Elective or urgent PCI</td>
<td>101</td>
<td>49</td>
<td>52</td>
<td>Intravenous bolus of 0.75 mg/kg, followed by a continuous infusion of 1.75 mg/kg/h</td>
<td>Intravenous bolus of 70 U/kg followed by an infusion of 20 U/kg/h to achieve and maintain an ACT of 200–250 s</td>
<td>13</td>
<td>56</td>
<td>30</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>SWITCH III, 2013</td>
<td>NSTEMI</td>
<td>100</td>
<td>98</td>
<td>51</td>
<td>Intravenous bolus of 0.75 mg/kg, followed by a continuous infusion of 1.75 mg/kg/h</td>
<td>Intravenous bolus of 60 U/kg with subsequent boluses to maintain an ACT &gt; 200 s</td>
<td>32</td>
<td>63</td>
<td>30</td>
<td>4</td>
<td>12</td>
</tr>
<tr>
<td>Xiang et al.</td>
<td>UA or elective PCI</td>
<td>218</td>
<td>110</td>
<td>108</td>
<td>Intravenous bolus of 0.75 mg/kg, followed by a continuous infusion of 1.75 mg/kg/h If ACT was &lt; 225 s, an additional bolus of 0.3 mg/kg was added</td>
<td>Intravenous bolus of 130 U/kg. If ACT was &lt; 225 s, an additional bolus of 300 U/kg was added</td>
<td>17</td>
<td>58</td>
<td>30</td>
<td>1</td>
<td>4</td>
</tr>
</tbody>
</table>

Continued
Publication bias was minimised by a comprehensive literature search. In addition, a graphical display (funnel plot) of the size of the treatment effect against the precision of the trial (1/SE) was used to investigate publication bias. All tests were two-sided, and statistical significance was fixed at 0.05 level. Analysis was carried out using Review Manager Software (RevMan V.5.3) and Stata V.11.2 (StataCorp, College Station, Texas, USA).

RESULTS
We identified 32 randomised trials comparing the effects of bivalirudin and UFH, and involving patients with ACS undergoing PCI. Of these, 19 trials involving 35,961 patients, that met the inclusion and exclusion criteria, were included in the meta-analysis. The methodological quality of included studies is described in online supplementary table S2. The primary outcomes of each trial are listed in online supplementary table S1. Most trials used a major bleeding definition based on either REPLACE-2 or ACUITY. There was no evidence of publication bias having a significant effect on the results (eg, see online supplementary figures S2 and S3).

The characteristics of individual STEMI trials are listed in table 1. Five trials enrolled 10,358 patients predominantly with STEMI, in which 82–97% underwent PCI. The characteristics of individual NSTE-ACS trials are listed in table 2. Four trials predominantly enrolled patients with NSTE-ACS, and 10 trials predominately enrolled patients with urgent or elective PCI for unstable or stable angina. In total, across the 14 NSTE-ACS trials, 24,979 (98.9%) of 25,238 patients underwent PCI. Bivalirudin doses were similar across all included trials (intravenous bolus of 0.75 mg/kg followed by an infusion of 1.75 mg/kg/h). UFH doses ranged between 50 U/kg, as in TENACITY and PROTECT-TIMI, and up to 140 U/kg, as in ISAR-REACT 3, with a median dose of 70 U/kg across all included trials.

In STEMI, there was no difference in the risk of death (OR 0.91; CI 0.72 to 1.15; p=0.42) between the two drugs. As compared with UFH, bivalirudin increased the risk of acute ST (OR 3.62; CI 1.95 to 6.74; p<0.0001) between the two drugs. As compared with UFH, bivalirudin increased the risk of acute ST (OR 3.62; CI 1.95 to 6.74; p<0.0001) between the two drugs. However, there was no
difference in the risk of major bleeding when both drugs were combined with provisional GPI (OR 0.98; CI 0.59 to 1.63; p=0.93) (figure 3B).

In NSTE-ACS, there was no difference between bivalirudin and UFH in the risk of death (OR 0.96; CI 0.64 to 1.45; p=0.86), MI (OR 1.09; CI 0.98 to 1.21; p=0.11), or any ST (OR 1.20; CI 0.84 to 1.70; p=0.31) (figure 4). Two NSTE-ACS trials reported no significant difference between bivalirudin and UFH in the risk of acute and subacute ST.21 25 Bivalirudin plus provisional GPI

**Figure 1** Death, myocardial infarction with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction (STEMI) studies; (A) death, (B) myocardial infarction.

**Figure 2** Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction (STEMI) studies; (A) any stent thrombosis, (B) acute stent thrombosis (<24 h), and (C) subacute stent thrombosis (≥24 h to 30 days).
reduced the risk of major bleeding compared with UFH plus planned GPI (OR 0.52; CI 0.45 to 0.62; p<0.00001) (figure 5A). Also, bivalirudin reduced the risk of major bleeding compared with UFH, with provisional use of GPI in both arms (OR 0.68; CI 0.46 to 1.01; p=0.05) (figure 5B). However, there was no difference in the risk of major bleeding when either drug was combined with planned GPI (OR 0.94; CI 0.57 to 1.53; p=0.79) (figure 5C). The results observed in NSTE-ACS were also observed within the group of trials that enrolled patients predominantly with NSTEMI (see online supplementary figure S4).

There was no significant relation between the reduction in bleeding with bivalirudin and mortality across all trials (p=0.96; see online supplementary figure S5). Also, there was no significant relation between the reduction in bleeding with bivalirudin and the use of transradial approach across all trials (p=0.49; see online supplementary figure S6), in predominantly STEMI trials (p=0.61), or in predominantly NSTE-ACS trials (p=0.15).

DISCUSSION

The use of bivalirudin during PCI has been the subject of much debate recently. Most evidence of benefit was obtained when bivalirudin monotherapy was compared with a combination therapy of UFH plus GPI. Therefore, the differing benefits seen with bivalirudin and UFH in PCI may be in part related to the differential rates of GPI use. In this meta-analysis of 19 trials involving 35,596 patients, we found that bivalirudin may confer an advantage over UFH in patients with NSTE-ACS undergoing PCI, while this was not so in patients with STEMI. This difference is attributable to substantially increased risk of acute ST in STEMI-treated patients and not in NSTE-ACS. Moreover, bivalirudin use was associated with a significant reduction in major bleeding in NSTE-ACS but not in STEMI, when compared with UFH and provisional GPI use in both arms. There was no significant difference in the incidence of death, MI, or any ST between bivalirudin and UFH treated patients for both types of ACS.

The potential advantage of bivalirudin on bleeding risk was significantly affected by the strategy for concomitant GPI use. Overall, bivalirudin monotherapy consistently reduced the risk of bleeding in both ACS cohorts compared with UFH plus planned GPI. In contrast, when the use of GPI was provisional in bivalirudin and UFH arms, a benefit of bivalirudin use was observed in NSTE-ACS but not in STEMI. This may be in part due to the fact that the studies in NSTE-ACS included ISAR-REACT 322 (figure 5B), in which a very high bolus dose of UFH (140 U/kg) was used, resulting in more bleeding outcomes in the UFH arm. Also, the transradial approach was used more in STEMI than in NSTE-ACS trials (43% vs 15%, p=0.09), an approach associated with overall reduced bleeding29 30 and therefore, perhaps negating the reduction in bleeding that may have been observed with bivalirudin had a transfemoral approach been used. However, in contrast to what one might expect, our meta-analysis suggests that the relative reduction in major bleeding with bivalirudin was probably non-vascular access site related and did not seem to depend on the transradial approach use across all included trials (p=0.49), or in independent ACS cohorts (STEMI (p=0.61) versus NSTE-ACS (p=0.15)).

In five NSTE-ACS studies, when GPI was planned in both arms, there was no difference in the risk of major bleeding. Our findings are further supported by the recently conducted MATRIX trials, which showed that transradial compared with transfemoral access reduced net adverse clinical events through a reduction in all-cause mortality and major bleeding in 8404 patients with ACS.
undergoing PCI.31 In a parallel trial to assess antithrombotic effects, about 95% of 7213 patients with ACS (56% STEMI and 44% NSTE-ACS) were also randomised to bivalirudin or UFH with provisional GPI use (4.6% in bivalirudin group vs 26% in UFH group).32 Reduction in all-cause mortality was seen with bivalirudin (1.7% vs 2.3%; RR 0.71; 95% CI 0.51 to 0.99), which was probably due to a reduction in major bleeding (1.4% vs 2.5%; RR 0.55; 95% CI 0.39 to 0.78), importantly with an independent bivalirudin impact on bleeding not related to the vascular access site. The rate of definite ST was higher with bivalirudin compared with UFH (1.0% vs 0.6%; RR 1.71; 95% CI 1.00 to 2.93). In contrast to our findings, although there has not been yet a published subgroup analysis of the MATRIX antithrombotic trial, the authors state that the findings were consistent across various subgroups (ie, STEMI vs NSTE-ACS).

In theory, continued bivalirudin infusion after PCI might decrease the risk of acute ST in patients with STEMI. The MATRIX optical coherence tomography (OCT) substudy will provide data on whether prolonged bivalirudin infusion, compared with intraprocedural-only

Figure 4  Death, myocardial infarction and any stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly non-ST segment elevation acute coronary syndrome (NSTE-ACS) studies; (A) death, (B) myocardial infarction, and (C) any stent thrombosis.

administration in patients undergoing PCI, reduces the initial increase in ST (residual thrombosis on stent struts) as evaluated by OCT at the end of PCI and at 3–5 days follow-up.33

Our findings, which incorporate data from recent trials, should help clinicians when selecting a periprocedural anticoagulant in different ACS cohorts undergoing PCI. In patients with STEMI, with generally high thrombus burden and with the increasing use of transradial approach and more potent oral antiplatelet therapy, bivalirudin does not appear to be superior to UFH, especially with provisional use of GPI as currently recommended. In comparison, in patients with NSTE-ACS with lower thrombus burden, our meta-analysis suggests that bivalirudin may be superior to UFH with provisional GPI use with regard to bleeding risk, but does not reduce risk of ischaemic events. The results of future trials of bivalirudin should provide more understanding of the clinical outcomes with this antithrombotic drug in different ACS cohorts undergoing PCI.

Study limitations
Our meta-analysis has several limitations. First, most trials in NSTE-ACS included a considerable proportion of patients with stable angina undergoing elective PCI. This cohort was also included in our study, as the trials did not report a separate analysis for the ACS cohort. That being said, similar treatment strategies were allowed for patients with stable angina in these trials. Second, we were unable to gain full access to the MATRIX antithrombotic trial 32 subgroup results to include in the meta-analysis section. Third, UFH doses were different across the trials, which may have impacted on differential bleeding outcomes in the ACS cohorts studied. Fourth, the trials included had differences in vascular access, drug design and definitions. Finally, the results of this meta-analysis are derived from study-level data and not from patient-level data. Additionally, one trial had been presented but not published.21 Also, many of the trials included were open label with a potential for high performance bias. Finally, most of the large studies were conducted in developed western countries and thus, may not be generalisable to other healthcare settings.

CONCLUSIONS
Although in STEMI, bivalirudin is associated with an increased risk of acute ST, it may confer an advantage...
over UFH in patients with NSTE-ACS undergoing PCI, with a reduction in non-vascular access site major bleeding and without an increase in ST. Large randomised studies are needed to elucidate more precisely the optimal PCI-related antithrombotic regimen for patients presenting with STEMI and NSTE-ACS in the contemporary era.

Acknowledgements The authors would like to thank Ashraf Nabhan, MD, and Keith Sullivan, PhD, for analytical support.

Contributors MF and MS did the literature search. All the authors analysed the data, interpreted the findings, drafted the manuscript, and approved the manuscript submitted.

Competing interests None declared.

Ethics approval All included studies in this meta-analysis obtained ethics approval.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES


29. Jolly SS, Amlani S, Hamon M, et al. Radial versus femoral access for coronary angiography or intervention and the impact on major


32. Valgimigli M. Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX: bivalirudin vs. heparin clinical trial—MATRIX. San Diego, CA, USA: American College of Cardiology, 2015.

Supplementary Appendix
Table of Contents

Supplemental Figure 1: PRISMA Flow Diagram .......................... 3

Supplemental Figure 2: Death with bivalirudin versus unfractionated heparin in predominantly NSTE-ACS studies, the funnel plot suggesting that publication bias was minimal ................................................................. 4

Supplemental Figure 3: Myocardial infarction with bivalirudin versus unfractionated heparin in predominantly NSTE-ACS studies, the funnel plot suggesting that publication bias was minimal ................................................................. 5

Supplemental Figure 4: Death, myocardial infarction, any stent thrombosis, and major bleeding with bivalirudin versus unfractionated heparin in predominantly NSTEMI studies .................................................................................. 6

Supplemental Figure 5: Relationship between the effect of bivalirudin on bleeding and mortality ........................................................................................................................................... 7

Supplemental Figure 6: Relationship between the effect of bivalirudin on bleeding and the use of transradial approach ........................................................................................................................................... 8

Supplemental Table 1: Primary Outcomes and Definition of Major Bleeding ................................................................. 9

Supplemental Table 2: The methodological quality assessment of included studies ................................................................. 11

References .............................................................................. 12
Supplemental Figure 1: PRISMA flow chart

Records identified through database searching (n = 817)

Identification

Additional records identified through other sources (n = 12)

Records after duplicates removed (n = 441)

Screening

Records screened (n = 441)

Eligibility

Records excluded (n = 409)

Full-text articles assessed for eligibility (n = 32)

Studies included in qualitative synthesis (n = 19)

Included

Studies included in quantitative synthesis (meta-analysis) (n = 19)

Full-text articles excluded, with reasons (n = 13)
- Included only stable angina patients [1]
- Fibrinolytic therapy [2-4]
- Addressed dosing or timing issues [5-8]
- No clinical outcomes [9-10]
- Balloon angioplasty only [11-13]
- Small study (<50 patients) [14]
Supplemental Figure 2: Death with bivalirudin versus unfractionated heparin in predominantly NSTE-ACS studies, the funnel plot suggesting that publication bias was minimal.
Supplemental Figure 3: Myocardial infarction with bivalirudin versus unfractionated heparin in predominantly NSTE-ACS studies, the funnel plot suggesting that publication bias was minimal.
Supplemental Figure 4: Death, myocardial infarction, any stent thrombosis, and major bleeding with bivalirudin versus unfractionated heparin in predominantly NSTEMI studies

(A) Death, (B) Myocardial infarction, (C) Any stent thrombosis, and (D) Major bleeding with GPI predominantly provisional in the bivalirudin arm versus planned use in the heparin arm.
Supplemental Figure 5: Relationship between the effect of bivalirudin on bleeding and mortality

The regression line is almost flat (slope -0.61), P=0.9539.
Supplemental Figure 6: Relationship between the effect of bivalirudin on bleeding and the use of transradial approach

The regression line is almost flat (slope -0.54), P=0.4985.
## Supplemental Table 1: Primary Outcomes and Definition of Major Bleeding

<table>
<thead>
<tr>
<th>Study</th>
<th>Primary Outcomes</th>
<th>Major Bleeding Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>REPLACE-2</td>
<td>Composite death, MI, urgent repeat revascularization and major bleeding</td>
<td>Non-CABG, intracranial, intracocular, retroperitoneal, 4gm Hgb decline without bleeding, 3gm Hgb decline with bleeding or ≥2U RBC transfusion</td>
</tr>
<tr>
<td>REPLACE-1</td>
<td>Composite death, MI and repeat revascularisation at 48 hours</td>
<td>Non-CABG, intracranial, intracocular, retroperitoneal, 3gm Hgb decline or ≥2U transfusion</td>
</tr>
<tr>
<td>PROTECT-TIMI 30</td>
<td>Coronary flow reserve or TIMI major bleeding</td>
<td>TIMI major or minor</td>
</tr>
<tr>
<td>ACUITY-PCI</td>
<td>Composite death, MI and unplanned revascularization or major bleeding or net clinical outcomes (composite ischaemia or major bleeding)</td>
<td>Non-CABG, intracranial, intracocular, access site haemorrhage requiring intervention, 5 cm hematoma, 4gm Hgb decline without bleeding, 3gm Hgb decline with bleeding or transfusion</td>
</tr>
<tr>
<td>ARNO</td>
<td>Major bleeding</td>
<td>Non-CABG, intracranial, intracocular, retroperitoneal, 4gm Hgb decline without bleeding, 3gm Hgb decline with bleeding or ≥2U RBC transfusion</td>
</tr>
<tr>
<td>HORIZONS-AMI</td>
<td>Composite death, MI and target vessel revascularization and stroke or major bleeding</td>
<td>Non-CABG, intracranial, intracocular, access site haemorrhage requiring intervention, 5 cm hematoma, 4gm Hgb decline without bleeding, 3gm Hgb decline with bleeding or transfusion</td>
</tr>
<tr>
<td>ISAR-REACT 3</td>
<td>Composite death, MI, urgent target vessel revascularization and major bleeding</td>
<td>Non-CABG, intracranial, intracocular, retroperitoneal, 4gm Hgb decline without bleeding, 3gm Hgb decline with bleeding or ≥2U RBC transfusion</td>
</tr>
<tr>
<td>NAPLES</td>
<td>Composite death, MI, urgent repeat revascularization and major bleeding</td>
<td>Intracranial, intracocular, retroperitoneal, access site haemorrhage requiring intervention, 4gm Hgb decline without bleeding, 3gm Hgb decline with bleeding or ≥2U transfusion</td>
</tr>
<tr>
<td>TENACITY</td>
<td>Composite death, MI and urgent target vessel revascularization</td>
<td>Non-CABG, intracranial, intracocular, retroperitoneal, 4gm Hgb decline without bleeding, 3gm Hgb decline with bleeding or ≥2U RBC transfusion</td>
</tr>
<tr>
<td>ISAR-REACT 4</td>
<td>Composite death, MI, urgent target vessel revascularization and major bleeding</td>
<td>Non-CABG, intracranial, intracocular, retroperitoneal, 4gm Hgb decline + overt bleeding or transfusion of at least 2 U</td>
</tr>
<tr>
<td>ARMYDA-7 BIVALVE</td>
<td>Composite death, MI, urgent target vessel revascularization and ST or any bleeding</td>
<td>Any bleeding</td>
</tr>
<tr>
<td>Deshpande et al.</td>
<td>post procedural time to sheath removal and ambulation of the patient</td>
<td>Non-CABG, intracranial, intracocular, retroperitoneal, 4gm Hgb decline without bleeding, 3gm Hgb decline with bleeding or ≥2U RBC transfusion</td>
</tr>
<tr>
<td>EUROMAX</td>
<td>Composite of death or major bleeding</td>
<td>Non-CABG, intracranial, intracocular, access site haemorrhage requiring intervention, retroperitoneal, 4gm Hgb decline without bleeding, 3gm Hgb decline with bleeding or transfusion</td>
</tr>
<tr>
<td>SWITCH III</td>
<td>Major bleeding</td>
<td>Fatal bleeding, intracranial, intracocular, retroperitoneal, 3gm Hgb decline with bleeding or ≥2U RBC transfusion</td>
</tr>
<tr>
<td>Xiang et al.</td>
<td>Composite death, MI and target vessel revascularization or ACT values or any bleeding</td>
<td>Non-CABG, intracranial, intracocular, retroperitoneal, 4gm Hgb decline without bleeding, 3gm Hgb decline with bleeding or ≥2U RBC transfusion</td>
</tr>
<tr>
<td>Heat-PPCI</td>
<td>Composite death, MI, stroke and unplanned target vessel revascularization or major bleeding</td>
<td>BARC 3-5</td>
</tr>
<tr>
<td>Study</td>
<td>Definition</td>
<td>Outcome</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>NAPLES III</td>
<td>Major bleeding</td>
<td>In-hospital intracranial, intraocular, retroperitoneal, access site haemorrhage requiring intervention, 4gm Hgb decline without bleeding, 3gm Hgb decline with bleeding or ≥2U transfusion</td>
</tr>
<tr>
<td>BRIGHT</td>
<td>Composite death, MI, urgent target vessel revascularization, stroke and major bleeding</td>
<td>BARC 3 or 5</td>
</tr>
<tr>
<td>BRAVE 4</td>
<td>Composite death, MI, unplanned revascularization, ST, stroke and major bleeding</td>
<td>Non-CABG, intracranial, intraocular, access site haemorrhage requiring intervention, 5 cm hematoma, 4gm Hgb decline without bleeding, 3gm Hgb decline with bleeding or transfusion</td>
</tr>
</tbody>
</table>

### Supplemental Table 2: The methodological quality assessment of included studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Randomisation Scheme</th>
<th>Blinding</th>
<th>Dropout Rate (%)</th>
<th>Endpoint adjudication</th>
<th>Potential Sources of Bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>REPLACE-2</td>
<td>By central telephone system</td>
<td>Double-blind</td>
<td>&lt;1%</td>
<td>By blinded central committee</td>
<td>None identified</td>
</tr>
<tr>
<td>REPLACE-1</td>
<td>By central telephone system</td>
<td>Open-label</td>
<td>Not reported</td>
<td>Central adjudication was not used</td>
<td>Performance bias, attrition bias</td>
</tr>
<tr>
<td>PROTECT-TIMI 30</td>
<td>By central permuted block design system</td>
<td>Open-label</td>
<td>&lt;1%</td>
<td>By blinded central committee</td>
<td>Performance bias</td>
</tr>
<tr>
<td>ACUITY-PCI</td>
<td>By interactive voice response system</td>
<td>Open-label</td>
<td>&lt;1%</td>
<td>By blinded central committee</td>
<td>Performance bias</td>
</tr>
<tr>
<td>ARNO *</td>
<td>Not reported</td>
<td>Open-label</td>
<td>Not reported</td>
<td>By blinded central committee</td>
<td>Selection bias, performance bias, attrition bias</td>
</tr>
<tr>
<td>HORIZONS-AMI</td>
<td>By interactive voice response system</td>
<td>Open-label</td>
<td>&lt;1%</td>
<td>By blinded central committee</td>
<td>Performance bias</td>
</tr>
<tr>
<td>ISAR-REACT 3</td>
<td>Not reported</td>
<td>Double-blind</td>
<td>&lt;1%</td>
<td>By blinded central committee</td>
<td>Selection bias</td>
</tr>
<tr>
<td>NAPLES</td>
<td>By block randomisation system</td>
<td>Open-label</td>
<td>Not reported</td>
<td>By blinded central committee</td>
<td>Performance bias, attrition bias</td>
</tr>
<tr>
<td>TENACITY</td>
<td>Not reported</td>
<td>Double-blind</td>
<td>Not reported</td>
<td>By central committee</td>
<td>Selection bias, attrition bias</td>
</tr>
<tr>
<td>ISAR-REACT 4</td>
<td>By double-dummy-drug system</td>
<td>Double-blind</td>
<td>&lt;1%</td>
<td>By blinded central committee</td>
<td>None identified</td>
</tr>
<tr>
<td>ARMYDA-7 BIVALVE</td>
<td>By random numbers system</td>
<td>Open-label</td>
<td>Not reported</td>
<td>By blinded central committee</td>
<td>Performance bias, attrition bias</td>
</tr>
<tr>
<td>Deshpande et al.</td>
<td>Not reported</td>
<td>Open-label</td>
<td>Not reported</td>
<td>Not reported</td>
<td>Selection bias, performance bias, attrition bias</td>
</tr>
<tr>
<td>EUROMAX</td>
<td>Not reported</td>
<td>Open-label</td>
<td>1%</td>
<td>By blinded central committee</td>
<td>Selection bias, Performance bias</td>
</tr>
<tr>
<td>SWITCH III</td>
<td>By block randomisation system</td>
<td>Open-label</td>
<td>0</td>
<td>Not reported</td>
<td>Performance bias</td>
</tr>
<tr>
<td>Xiang et al.</td>
<td>Not reported</td>
<td>Single-blind</td>
<td>4%</td>
<td>Not reported</td>
<td>Selection bias, Performance bias</td>
</tr>
<tr>
<td>Heat-PPCI</td>
<td>By computerized randomisation system</td>
<td>Open-label</td>
<td>&lt;1%</td>
<td>By blinded central committee</td>
<td>Performance bias</td>
</tr>
<tr>
<td>NAPLES III</td>
<td>Not reported</td>
<td>Double-blind</td>
<td>0</td>
<td>By central committee</td>
<td>Selection bias</td>
</tr>
<tr>
<td>BRIGHT</td>
<td>Not reported</td>
<td>Single-blind</td>
<td>&lt;1%</td>
<td>By central committee</td>
<td>Selection bias</td>
</tr>
<tr>
<td>BRAVE 4</td>
<td>Not reported</td>
<td>Open-label</td>
<td>&lt;1%</td>
<td>By blinded central committee</td>
<td>Selection bias, performance bias, premature termination of the trial</td>
</tr>
</tbody>
</table>

* The trial had been presented, but not published.
References:


